Tag: melanoma

28 Jun

Zantrene shows impressive synergy with BRAF & MEK inhibitors in treating melanoma

Daniel Tillett ASX Release, Featured, Media Release , ,

28 June 2022 – Race Oncology Limited (“Race”) is pleased to share the final results from our preclinical melanoma research program in collaboration with the University of Newcastle (ASX announcement: 19 March 2021). This program aimed to explore the use…

Read More
30 Sep

Zantrene kills melanoma cancer cells that overproduce FTO

Daniel Tillett ASX Release, Featured , , ,

Zantrene at low concentrations kills high FTO producing melanoma cancer cells Sensitivity to Zantrene correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells Results are highly supportive of future…

Read More